AGV05

AGV05 is an early-stage small molecule oncology candidate being developed by AGV Discovery. Currently in the hit-to-lead phase of preclinical development, AGV05 was identified using the company's Fragment-Based Drug Design (FBDD) platform. AGV Discovery focuses on developing therapies for advanced cancers, with a particular research emphasis on cancer stem cells and circulating tumor cells, often in the context of advanced colorectal cancers. While the specific molecular target for AGV05 has not been publicly disclosed, it represents one of the core programs in the company's internal pipeline aimed at addressing unmet needs in oncology.